Signal: Top tweets of the week dissect impact of obesity drugs
08 Aug 2023
Drug ApprovalFast Track
Preview
Source: Pharmaceutical Technology
Manasi Vaidya
@manasivaidya22
Preview
Source: Pharmaceutical Technology
Credit: Shutterstock/Emre Akkoyun
As Eli Lilly gears up for releasing its Q2 earnings today, a key revenue and growth opportunity for the company—obesity drugs, continue to be in the news. In the last few weeks, regulatory agencies in the European Union and the UK have announced investigations into the link between GLP1 receptor agonists to suicidal ideation.
Are the new weight-loss/diabetes drugs safe? The @US_FDA & its European counterparts are investigating suicidal ideations in people taking semaglutide — the active ingredient in #ozempic & #Wegovy; liraglutide — the active ingredient in #Saxenda.
And now all so-called GLP-1…
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Diazoxide Choline Cr in Obesity GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Amylin AgonistAmylin Agonist Long Acting in Obesity GlobalData
View allCompanies IntelligenceLilly GmbHFastTrack Pty LtdEli Lilly Holdings LimitedView all— Laurie Garrett (@Laurie_Garrett) July 28, 2023
Eli Lilly’s blockbuster, Mounjaro (tirzepatide) is approved as an adjunct to diet and exercise to help patients with type 2 diabetes improve their glycemic control. However, it is currently used off label as an obesity medication, and has a Fast Track designation for official on-label use for that purpose. Moreover, Lilly’s investigational drug retatrutide, which targets GLP-1R, the gastric inhibitory polypeptide receptor (GIPR), and glucagon receptor (GCGR), has also generated significant investor interest for its potential as a weight-loss drug.
In the coming months, sales revenues for these drugs are expected to grow significantly. However, access comes with its own challenges due to drug shortages, and the need to navigate complex reimbursement dynamics.
How plan sponsors, insurers are considering coverage of weight-loss drugs amid rising use of #Ozempic https://t.co/tdD6FS5iRw@peoplecorp @SuzanneLepage @MedavieBC @beneva_ca #obesity pic.twitter.com/3G9pwWEzg7
— Benefits Canada (@BenCanMag) July 20, 2023
Additionally, as research on drugs like semaglutide accumulate, others are also debating the additional effects that are often widely shared on social platforms.
Some gurus are using semaglutide for longevity. Not related to diabetes or fat loss. Mechanism? I don't know. Seems unlikely.
— Bill Lagakos (@CaloriesProper) July 28, 2023
Our signals coverage is powered by GlobalData’s Disruptor data, which tracks all major deals, patents, company filings, hiring patterns and social media buzz across our sectors. These signals help us to uncover key innovation areas in the sector and the themes that drive them. They tell us about the topics on the minds of business leaders and investors, and indicate where leading companies are focusing their investment, deal-making and R&D efforts.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.